Menstrual cycle timing may change how exercise impacts blood sugar in type 1 diabetes
NCT ID NCT05188014
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study looks at how different phases of the menstrual cycle affect blood glucose changes during exercise in women with type 1 diabetes who take oral contraceptives. Participants wear a continuous glucose monitor and complete a 45-minute aerobic exercise session during both the active pill phase and the placebo pill phase. The goal is to understand whether cycle timing influences blood sugar responses, which could help women with type 1 diabetes tailor their exercise routines.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help women with type 1 diabetes better manage their blood sugar during exercise by accounting for menstrual cycle timing.
- What could go wrong
- This is a small, early-stage observational study with only 15 participants, so findings may not apply to all women with type 1 diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2022
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * type 1 diabetes diagnosed for at least 1 year * regular menses * using monophasic oral contraceptives * residing in Edmonton, Alberta and able to visit the lab at the University of Alberta Exclusion Criteria: * HbA1c \> 9.9% * frequent and unpredictable hypoglycemia * change in insulin management strategy within two months of the study * use of an automated insulin delivery system * blood pressure \> 140/95 * history of cardiovascular disease * severe peripheral neuropathy * active proliferative retinopathy * use of medications (other than insulin) that would affect blood glucose levels * any musculoskeletal condition that would contraindicate exercise (e.g. sprain, strain, joint injury, etc.)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Alberta Diabetes Institute
RECRUITINGEdmonton, Alberta, T6G 2R3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Clinical and biological responses to repeated administration of low-dose Interleukin-2 in patients with type 1 diabetes and a residual insulin secretion
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Can an automated pancreas system make type 1 diabetes safer in the real world?
- A new way to dose insulin without carb counting?
- A smart insulin calculator may give kids with diabetes more freedom at mealtimes
- Virtual reality mindfulness: a new way to ease stress in young adults with diabetes?